Jazz Pharmaceuticals invests €50m in new manufacturing plant
Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced that it has commenced construction of a manufacturing and development facility to be located on a 17-acre site in Monksland, County Roscommon, approximately 75 miles east of the company’s Dublin headquarters. This is the first manufacturing facility to be built by Jazz Pharmaceuticals.
“Today marks a milestone for Jazz Pharmaceuticals as we break ground in Ireland and begin, for the first time, construction on a manufacturing and development facility,” said Bruce Cozadd, Chairman and Chief Executive Officer of Jazz Pharmaceuticals plc.
“This investment not only strengthens our international manufacturing capabilities, but importantly represents our commitment to expanding our presence in Ireland. We are grateful for the partnership of IDA Ireland and Roscommon County Council who helped make this project possible.”
Members of the Board of Directors and employees of Jazz Pharmaceuticals were joined by the Taoiseach of Ireland, Mr. Enda Kenny TD and Mr. Barry O’Leary, CEO, IDA Ireland, during a ground-breaking ceremony today. At the ceremony, Mr. Cozadd outlined the company’s plans to commence construction immediately, with an anticipated completion date in 2016. Jazz Pharmaceuticals expects to invest approximately $60 – $68 million (€45 – €50 million) in construction, development and personnel costs to build and open the 55,000 ft2 (5,100 m2) facility.
The investment is being supported by the Irish Government’s Department of Jobs, Enterprise and Innovation through IDA Ireland.
“I’m delighted to be here for the ground-breaking of Jazz Pharmaceuticals’ new manufacturing facility in Roscommon. This is a great boost for the local area and the 160 jobs being created in the construction phase will provide an opportunity for some of those people who lost jobs in this sector in recent years. The new facility will also create up to 50 new jobs when operating at full capacity,” said the Taoiseach, Mr. Enda Kenny TD during the ground-breaking ceremony. “I welcome the decision by Jazz Pharmaceuticals to locate in Ireland which is a vote of confidence in our economy and Government policy, like the Action Plan for Jobs, which is targeted towards supporting sectors with the greatest potential to generate jobs.”
“Jazz Pharmaceuticals’ decision to build a manufacturing site in Ireland is testament to the excellent reputation Ireland has as a global location for biopharmaceutical development and manufacturing,” said Mr. Barry O’Leary, CEO IDA Ireland. “This is a strategically important development for Jazz Pharmaceuticals and Ireland is well placed to support manufacturing for the company’s growing commercial portfolio.”
Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, hematology/oncology, pain and psychiatry. The company’s U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, FazaClo® (clozapine, USP) HD and FazaClo LD. Jazz Pharmaceuticals also has a number of products marketed outside the U.S. and expects to launch Defitelio™ (defibrotide) in the European Union over the course of 2014.